PURASORB PLDL 7060, a 70/30 L-lactide/DL-lactide copolymer with an inherent viscosity midpoint of 0.6 dL/g and an amorphous morphology, is processed directly into craniomaxillofacial osteosynthesis components by injection moulding after vacuum drying at 80 °C to a residual moisture content below 250 ppm. The resin is supplied under an ISO 13485:2016 quality management system and is specified for lactide-based implant copolymers under ISO 15814:2000; biological evaluation is planned and documented according to ISO 10993-1:2018, with degradation product characterization performed per ISO 10993-13:2010. For low-load midface and cranial fixation, the polymer is either processed unfilled at 100 wt% or compounded with 10–25 wt% beta-tricalcium phosphate to moderate pH drift during hydrolytic degradation. Injection moulding is performed on a 30:1 L/D two-stage screw with a compression ratio of 2.2:1 to 2.5:1; barrel profile is held at 160–185 °C, nozzle at 185 °C, and chilled mould at 25–40 °C to prevent lactide reformation. Production-scale equipment behaviour has shown that residence time beyond 15 min at melt temperature above 190 °C yields an increase in residual lactide and a measurable drop in intrinsic viscosity above 0.08 dL/g. Terminal device forms include 1.5 mm, 2.0 mm, and 2.5 mm orbital floor plates, maxillofacial mesh sheets, and interference screws for mandibular fracture fixation. Mechanical properties are generated according to ISO 527-2:2012 and ASTM D638-14; in vitro hydrolytic stability is evaluated per ASTM F1635-16 in phosphate-buffered saline at 37 °C and pH 7.4. The amorphous 70/30 L/DL lactide copolymer loses load-bearing capacity more rapidly than crystalline PLLA, restricting use to non-load-bearing or low-load craniofacial indications where the shorter strength-retention window is clinically acceptable.

Solvent-Cast Barrier Membranes in Guided Bone Regeneration

Solvent-cast guided bone regeneration membranes use PURASORB PLDL 7060 at 5–15 wt% in ethyl acetate or acetone, with 0–30 wt% hydroxyapatite or beta-tricalcium phosphate relative to polymer solids when osteoconductive surface properties are required. The polymer is amorphous with a glass transition temperature of 55–60 °C, so the dried film retains ductility without post-crystallization annealing, and the absence of crystalline domains avoids stiffening during storage below ambient temperatures. Downstream production begins with dissolution under reflux at 50–60 °C, followed by vacuum degassing and doctor blade casting onto a polyester release liner with a wet film gap of 300–800 µm. Two-stage drying at 25 °C and 45 °C is followed by vacuum extraction at 40 °C for 12–24 h to reduce residual solvent below 0.5 % w/w. Residual solvent is quantified by headspace gas chromatography per ISO 10993-18:2020, and sterile membrane packaging is maintained under ISO 13485:2016, 7.5.2. Biological evaluation is conducted according to ISO 10993-1:2018 and ISO 10993-5:2009 for cytotoxicity, with implantation studies performed under ISO 10993-6:2016. Terminal product types include resorbable dental barrier membranes for guided bone regeneration, periodontal defect coverage, and implant site protection, with finished thickness between 100 µm and 300 µm. Processing boundary data from membrane converting show that films exposed to relative humidity above 60 % before primary packaging undergo glass transition depression and blocking; lamination and pouch sealing are therefore performed in dry air with dew point controlled below −20 °C.

During oil-in-water solvent evaporation for injectable depot microparticles, PURASORB PLDL 7060 is dissolved in dichloromethane at 10–30 % w/v, and the active pharmaceutical ingredient or imaging agent is added at 5–25 % w/w relative to polymer according to the release target. The organic phase is emulsified into a continuous aqueous phase containing 0.5–2.0 wt% poly(vinyl alcohol) at 300–800 rpm; particle hardening occurs by solvent extraction into excess aqueous phase at 15–25 °C for 3–6 h. The resulting microspheres are collected by centrifugation, washed with water for injection, and lyophilized at −40 °C shelf temperature for 24–48 h. Particle size distribution is measured by laser diffraction per ISO 13320:2020; bulk density and syringability are evaluated with 20G–23G injection needles under controlled plunger force. The copolymer must be moisture-free before dissolution because residual moisture above 500 ppm causes premature polymer hydrolysis during solvent evaporation and broadens particle size distribution, increasing batch-to-batch coefficient of variation. Terminal device types include injectable biodegradable depot microspheres for sustained release, embolization microspheres, and injectable bulking matrices where resorbable particle size must remain within 20–200 µm. Regulatory compliance includes ISO 10993-1:2018 and USP <788> for particulate matter in injections; for drug-led combination products, FDA 21 CFR 210/211 current good manufacturing practice applies. Published degradation data for this specific 7060 microparticle depot configuration is limited, and release kinetics must be generated under final formulation conditions rather than transferred from higher molecular weight PLGA grades.

Why Is an Amorphous 70/30 L/DL Lactide Copolymer Selected over Crystalline PLLA for Adhesion Barrier Films?

For post-surgical adhesion barrier film, the selection of PLDL 7060 over crystalline PLLA is based on the absence of crystallites that can generate localized acidic degradation pockets and the requirement for a conformable film that does not crack when draped over viscera or wrapped around tendon during placement. Melt-extruded films are produced at 100 wt% PLDL 7060 without additives; if greater flexibility below ambient temperature is required, up to 10 wt% of a medical-grade plasticizer may be incorporated by melt compounding, but published degradation data for plasticized 7060 film configurations is limited. Downstream film production uses a single-screw extruder with 25:1 L/D and barrier screw, melt temperature 160–180 °C, flat die with 200–300 µm die gap, and polished chill roll at 15–25 °C; film thickness is controlled to 20–150 µm. Alternatively, solvent casting uses 5–12 wt% polymer in ethyl acetate with subsequent vacuum drying. Finished film is cut to 50 mm × 100 mm or 100 mm × 200 mm formats for sterile packaging. Biocompatibility is evaluated per ISO 10993-1:2018, ISO 10993-6:2016 for implantation, ISO 10993-10:2013 for irritation, and ISO 10993-17:2023 for leachables risk assessment; the manufacturing line is audited under ISO 13485:2016. Processing boundary data show that polymer held at 180 °C for more than 20 min exhibits viscosity loss greater than 0.1 dL/g; continuous extrusion with controlled feed is therefore preferred over hot-melt batch processing. Terminal product types include intraperitoneal adhesion barrier film, pericardial adhesion barrier sheet, and tendon wrap for reconstruction, with in vivo residence time governed by the 70/30 L/DL comonomer ratio and final film thickness.

Electrospinning of PLDL 7060 from hexafluoroisopropanol or a chloroform/dimethylformamide mixture at 5–10 wt% polymer concentration produces fibre diameters of 0.5–2.0 µm suitable for dermal and vascular scaffold matrices. The solution is loaded into a stainless steel syringe pump and electrospun at 15–25 kV applied voltage, 10–20 cm tip-to-collector distance, and 0.5–2.0 mL/h flow rate onto a rotating mandrel at 500–1,500 rpm. To modify hydrophilicity and cell attachment, the polymer solution may be blended with 10–20 wt% gelatin or 5–15 wt% poly(ethylene glycol) relative to total polymer; phase separation in chloroform systems is controlled by maintaining relative humidity below 40 %. Scaffolds are dried under vacuum at 25 °C for 24 h to reduce residual solvent below 500 ppm. Compliance is established through ISO 10993-1:2018, ISO 10993-5:2009 for cytocompatibility, and ISO 10993-6:2016 for implantation response. Terminal products include resorbable electrospun vascular graft scaffolds, wound healing matrices, and nerve conduit tubes with wall thickness 100–400 µm. Operation records show that batch-to-batch inherent viscosity variation from 0.55 dL/g to 0.65 dL/g changes fibre diameter at constant voltage; in-process viscosity checks and conductivity adjustment are recommended before large-scale production runs.

When PLDL 7060 Replaces Crystalline PLLA in Drug-Eluting Implant Coating Layers

Drug-eluting implant coating layers formulated with PLDL 7060 are applied by precision spray coating at 0.5–2.0 wt% polymer in acetone or ethyl acetate, with active agent loading 10–30 wt% relative to polymer. The amorphous 70/30 L/DL lactide copolymer provides a more uniform drug distribution than semi-crystalline PLLA because phase-separated crystalline domains are absent, but the lower glass transition temperature of 55–60 °C necessitates moisture-controlled handling and cold storage of coated intermediates. Coating is performed in an ultralow-humidity nitrogen atmosphere with relative humidity below 10 %, nozzle atomisation pressure 0.5–1.5 bar, substrate temperature 15–25 °C, and layer-by-layer deposition to achieve coating thickness 5–30 µm; between layers, solvent is removed under vacuum at 30 °C for 10–20 min. Adhesion to metallic substrates is assessed by cross-cut tape test according to ISO 2409:2020; drug release is measured by USP apparatus 7 in phosphate buffer pH 7.4 at 37 °C. Hemocompatibility is evaluated per ISO 10993-4:2017, and leachables are characterized per ISO 10993-18:2020. Terminal products include drug-eluting stent coatings, orthopaedic trauma screw coatings, and antimicrobial implant sleeves. Processing boundary data show that coating thickness above 30 µm and drug loading above 40 wt% may cause delamination after ethylene oxide sterilization; process validation per ISO 13485:2016, 7.5.6 is mandatory before production release.